Cardiff Oncology, Inc. · NASDAQ:CRDF
Cardiff Oncology — Corporate Update (September 2023)
26 slides from Cardiff Oncology's corporate update, September 2023
Slide 1: Pancreatic Cancer and Small Cell Lung Cancer Program Updates
Pancreatic Cancer and Small Cell Lung Cancer Program Updates
Slide 2: Forward-looking statements
Forward-looking statements CERTAIN STATEMENTS IN THIS PRESENTATION ARE FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995, These statements may be identified by the use of words such as “anticipate,” "believe," "forecast," "estimated" and "intend" or other sim
Slide 3: Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) and Small Cell Lung Cancer (SCLC)
Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) • • • Small Cell Lung Cancer (SCLC) •
Slide 4: Onvansertib
Onvansertib PROPERTIES SPECIFICITY • • •
Slide 5: Line of Therapy Trial
Line of Therapy Trial IIT* Ph2 Ph3 Combination with:
Slide 6: Annual eligible U.S. patients by target
Annual eligible U.S. patients (’000s)* Targets with Targets without oncogenic oncogenic alterations alterations 50 48 50 15 12 3 5 * ROS1 estimated eligible patients presented in mCRC estimated population includes 1st line, Turning Point Therapeutics’ corporate KRAS- and NRAS-mutated cancers. mPDAC
Slide 7: Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Small Cell Lung Cancer (SCLC)
Slide 8: Path forward: Move to 1st line mPDAC
mPDAC mPDAC CRDF-001 Ph 2 Second-Line Trial Biomarker Discovery Trial (IIT) • • Path forward: Move to 1st line mPDAC •
Slide 9: Path forward: Move to 1st line mPDAC
mPDAC mPDAC CRDF-001 Ph 2 Second-Line Trial Biomarker Discovery Trial (IIT) • • Path forward: Move to 1st line mPDAC •
Slide 10: CRDF-001 trial design: 14 day cycle
ENROLLMENT CRITERIA OBJECTIVE PRIMARY ENDPOINT 14 DAY SECONDARY ENDPOINT CYCLE
Slide 11: Confirmed PR, waiting for confirmatory scan
Confirmed PR Waiting for confirmatory scan
Slide 12: Stable disease patients have converted to partial responses over time
Stable disease patients have converted to partial responses over time Swimmer plot — 23 evaluable patients (as of September 13, 2023)* Q oO ie} 085 te} e e Reason for Discontinuation (o} [e) Adverse Event — — 7 Death Disease Progression (} e e @ Withdrawal of Informed Consent Response oO @ Progressi
Slide 13: Confirmed PR, waiting for confirmatory scan
Confirmed PR Waiting for confirmatory scan
Slide 14: Onvansertib+SoC has longer median PFS than 2nd line historical controls
Onvansertib+SoC has longer median PFS than 2"9 line historical controls Progression-free survival — 23 evaluable patients (as of September 13, 2023)* Historical controls! 24 line 1% line CRDF-001 mPDAC mPDAC mPFS 5.0mos 3.1 mos 5.5 mos 16 week Not progression- 56% ‘labl 48% free? available mber 13,
Slide 15: Path forward: Move to 1st line mPDAC
mPDAC mPDAC CRDF-001 Ph 2 Second-Line Trial Biomarker Discovery Trial (IIT) • • Path forward: Move to 1st line mPDAC •
Slide 16: Biomarker discovery trial: enrollment criteria and objectives
ENROLLMENT CRITERIA OBJECTIVES • •
Slide 17: Patient 28 (responder) vs Patient 33 (non-responder)
• • Patient 28 (tumor responder) Patient 33 (tumor non-responder) 30 150k 40 1500 30 20 100k 1000 20 10 50k 500 10 0 0k 0 0
Slide 18: Path forward: Move to 1st line mPDAC
mPDAC mPDAC CRDF-001 Ph 2 Second-Line Trial Biomarker Discovery Trial (IIT) • • Path forward: Move to 1st line mPDAC •
Slide 19: First-line mPDAC trial design: 28 day cycle
SUBSEQUENT CHEMO + ENROLLMENT CRITERIA TWO LEAD-IN COHORTS ONVANSERTIB TREATMENT* • • PRIMARY ENDPOINT 28 DAY CYCLE SECONDARY ENDPOINTS
Slide 20: Small Cell Lung Cancer (SCLC)
Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Small Cell Lung Cancer (SCLC)
Slide 21: Onvansertib demonstrates single-agent activity in preclinical SCLC models
Onvansertib demonstrates single-agent activity in preclinical SCLC models TRIAL RATIONALE Onvansertib monotherapy showed significant tumor growth inhibition against platinum-sensitive and -resistant models Tumor volume (mm3) >, cisplatin 3mg/kg IP weekly In vivo efficacy of onvansertib monotherapy (
Slide 22: SCLC trial design: 21 day cycle
ENROLLMENT CRITERIA OBJECTIVE PRIMARY ENDPOINT 21 DAY CYCLE SECONDARY ENDPOINTS
Slide 23: Preliminary safety and efficacy
ENROLLMENT CRITERIA PRELIMINARY SAFETY (N=6) PRELIMINARY EFFICACY (N=7)
Slide 24: Baseline scan and restaging after Cycle 2
Baseline Scan Restaging after Cycle 2
Slide 25: Upcoming data readouts 2023-2025
2023 2024 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 1st line mCRC mPDAC randomized data readout data readout SCLC data readout
Slide 26: Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) and Small Cell Lung Cancer (SCLC)
Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) • • • Small Cell Lung Cancer (SCLC) •